AI-generated analysis
EQT's exit from Galderma Group AG through a record-breaking block trade underscores the strategic success of its ownership period, which saw significant growth and market penetration in the dermatology sector. Under EQT’s stewardship since 2019, Galderma has transformed into a leader with double-digit revenue growth, increased margins by 5 percentage points, and more than doubled EBITDA from $520 million to over $1.2 billion. The company's public offering in 2024 was one of Europe’s largest IPOs, with its share price nearly tripling since listing.
The transaction mechanics involve the placement of approximately 34 million shares for gross proceeds of CHF 4.9 billion, highlighting Galderma's robust financial performance and investor appetite. This exit strategy allowed EQT to generate substantial returns, realizing over $26 billion in total proceeds across various sell-downs since the IPO.
The deal significantly alters competitive dynamics within dermatology by solidifying Galderma’s market position through a combination of strong organic growth and strategic product launches like Nemluvio and Relfydess. This enhances its capability to compete against established players such as L'Oréal, Allergan (now part of AbbVie), and Bayer.
Looking ahead, key risks for Galderma include regulatory scrutiny for new product launches, maintaining high research and development investment rates, and navigating potential market saturation in injectable aesthetics. Integration challenges may arise from balancing organic growth with strategic acquisitions to sustain momentum post-IPO. However, the strong commercial execution and diversified portfolio provide robust growth vectors, positioning Galderma well for continued leadership in dermatology.
Galderma Group AG (CH), the skincare and dermatology company, announced on Tuesday its full exit from a strategic carve-out through a public placement valued at $6.1 billion.
| Acquirer: |
|
Target: |
Galderma Group AG (CH) |
| Deal type: |
|
Type: |
Carve-out |
| Close date: |
|
Close Date: |
2026-03-13 |
| Value: |
|
Deal value: |
$6.1bn |
| Announcement date: |
|
Announced Date: |
2026-03-13 |
| Buy-side advisor(s): |
|
Buy-side advisors: |
Not disclosed |
| Sell-side advisor(s): |
|
Sell-side advisors: |
Not disclosed |
| Legal buy-side: |
|
Legal (buy-side): |
Not disclosed |
| Legal sell-side: |
|
Legal (sell-side): |
Not disclosed |
Deal Mechanics
The sale of Galderma Group AG was executed through a public placement, marking the largest sponsor-backed block trade to date. EQT, the current owner, sought to divest its entire stake in the skincare and dermatology firm.
Strategic Rationale
EQT's strategic decision to exit Galderma Group AG is rooted in the company’s robust financial performance and growth potential. Over recent years, Galderma Group AG has achieved double-digit revenue growth alongside a significant 5 percentage point increase in margins. The firm also saw its EBITDA more than double during this period.
The deal includes several transformative product launches that are expected to further bolster the company's market position and profitability going forward.
Financial Context
Globally, Galderma Group AG is recognized for its leadership in dermatology treatments and skincare solutions. The company’s strong track record of financial performance and strategic product pipeline aligns with broader trends in the healthcare sector towards innovation-driven growth and expansion into high-demand therapeutic areas.